microbiome-derived peptide vaccine EO2463

A microbiome therapeutic cancer peptide vaccine composed of onco-mimics, immunogenic microbiome-derived peptides that are highly homologous to specific tumor-associated antigens (TAAs), that are obtained and selected from the human gut microbiome, with potential immunomodulating and antineoplastic activities. The microbiome-derived bacterial antigens in EO2463 mimic TAAs that are highly expressed by malignant B cells. Upon administration of microbiome-derived peptide vaccine EO2463, the peptides are taken up by and presented on dendritic cells (DCs) to T cells. As the presented antigens display molecular mimicry with selected TAAs on malignant B cells, a memory T-cell- and cytotoxic T-lymphocyte (CTL)-mediated immune response may be mounted against the TAAs expressed on the malignant B cells, thereby eradicating the cancer cells.